AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Shein Reports $99 Million Loss Ahead of Hong Kong IPO as U.S. Tariffs Hit Sales 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
Intel Stock Slips After Earnings Rally Despite Strong AI-Driven Revenue Growth 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Shares of Sino Biopharmaceutical (HK:1177) climbed on Wednesday after the Chinese pharmaceutical company announced a major licensing agreement with AstraZeneca (ST:AZN) and expanded its strategic commercial partnership with GSK plc (LON:GSK), strengthening its position in the global respiratory medicine market.
Under the agreement, Sino Biopharm's subsidiary, Chia Tai Tianqing Pharmaceutical Group, granted AstraZeneca exclusive rights to develop, manufacture, and commercialize its experimental inhaled PDE3/4 inhibitor, TQC3721, in markets outside China. The investigational respiratory treatment represents another milestone in Sino Biopharm's strategy to monetize its research pipeline through international collaborations.
As part of the deal, AstraZeneca will pay Sino Biopharm an upfront payment of $200 million. The Chinese drugmaker is also eligible to receive up to $1.9 billion in potential development, regulatory, and commercial milestone payments. In addition, the company will earn tiered double-digit royalties based on annual net sales if the treatment reaches the market.
Separately, Sino Biopharm announced an expanded partnership with GSK, securing commercialization rights in mainland China for the respiratory therapies Trelegy Ellipta and Anoro Ellipta. The company will oversee product importation, distribution, hospital access, and promotional activities across China, while recognizing revenue generated from domestic sales.
The announcements boosted investor sentiment, sending Sino Biopharm shares up as much as 7% to HK$5.15 during Wednesday's trading session before the stock trimmed part of its gains.
The latest agreements build on Sino Biopharm's growing network of partnerships with leading global pharmaceutical companies. Earlier this year, the company licensed selected rights for TQC3721 to Sanofi, while in May it entered a strategic collaboration with GSK to support the launch of hepatitis B treatment bepirovirsen in China.
Over the past several years, Sino Biopharm has accelerated its cross-border licensing strategy and commercial alliances, aiming to expand its international footprint, unlock the value of its innovative drug pipeline, and strengthen long-term revenue growth through partnerships with multinational pharmaceutical companies.
